Citigroup initiated coverage on Arrowhead with a new price target
$ARWR
Biotechnology: Pharmaceutical Preparations
Health Care
Citigroup initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $33.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/5/2024 | $31.00 | Neutral | Goldman |
| 12/4/2023 | $29.00 | Buy | BofA Securities |
| 9/19/2023 | $33.00 | Neutral | Citigroup |
| 7/21/2023 | Outperform | TD Cowen | |
| 5/12/2023 | $40.00 | Outperform → Market Perform | SVB Securities |
| 4/26/2023 | $80.00 | Outperform | SMBC Nikko |
| 4/12/2023 | $21.00 → $35.00 | Market Perform → Outperform | SVB Securities |
| 3/21/2023 | $27.00 | Mkt Perform | Bernstein |
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
- Conference Call and Webcast Today, November 26, 2024, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference call today, November 26, 2024, at 4:30 p.m. ET to discuss the results. "Arrowhead is well positioned, both individually and with partners, to advance and ultimately commercialize important new medicines using our proprietary TRiM™ technology. We have the potential to impact the lives of millions of patients in need. We believe we now have all the necessary pieces in place to drive significant value for shareholders in the short-term, mid-term, and, mor
– Sarepta obtains exclusive worldwide licenses to four clinical-stage and three preclinical-stage programs in muscle, central nervous system, and rare pulmonary disorders, including potential best-in-class siRNA-based treatments for DM1 and FSHD – Additionally, Arrowhead and Sarepta have entered into a discovery partnership pursuant to which Sarepta will nominate, and Arrowhead will deliver, IND-ready constructs for six targets across skeletal muscle, cardiac, and CNS – Investigational treatments leverage Arrowhead's leading Targeted RNAi Molecule (TRiMTM) platform, capable of deep and durable target-gene knockdown – Upon closing, Arrowhead to receive $500 million in an upfront paymen
- Upon closing, Arrowhead will receive $825 million immediately, including an upfront payment and an equity investment at a 35% premium, and will receive an additional $250 million paid over five years - Arrowhead has potential to receive an additional $300 million in near-term clinical trial enrollment-related milestone payments and is eligible for future potential milestone payments up to $10 billion and royalties on sales - Sarepta to receive investigational treatments that leverage Arrowhead's leading Targeted RNAi Molecule platform - Arrowhead to discuss this agreement during the company's 2024 fiscal year end results conference call today, November 26, 2024, at 4:30 p.m. ET Ar
Goldman initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $31.00
BofA Securities initiated coverage of Arrowhead with a rating of Buy and set a new price target of $29.00
Citigroup initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $33.00
- The New Drug Application is based on positive results from the Phase 3 PALISADE study - People living with familial chylomicronemia syndrome have extremely high triglyceride levels and a substantially higher risk of developing acute pancreatitis and associated long-term complications, including poor quality of life Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease. The FDA provided a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, a
- ARO-INHBE targets a known pathway that signals the body to store fat in adipose tissue - In preclinical studies ARO-INHBE reduced body weight and fat mass with a novel mechanism of action that may better preserve lean muscle mass compared to currently approved obesity therapies Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. Arrowhead also filed recently a request for regulatory clearance to initiate a clinical trial for its second obesity candidate, ARO-ALK7. Bo
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that as an inducement to entering into employment with the Company, on December 13, 2024, the Company's Board of Directors approved "inducement" grants to 20 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 44,350 restricted stock units. The grants are outside the Company's stockholder-approved equity incentive plans and vest annually over four years. About Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and effici
SC 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that the board of directors appointed veteran pharmaceutical industry executive Victoria Vakiener, as an independent director of the company, with a term beginning effective May 2, 2022. Douglass Given, M.D., Ph.D., Chairman of the Board of Arrowhead said, "Vicki is a senior executive with an impressive track record of leading organizations to successfully commercialize important medicines." "I've watched Arrowhead aggressively grow its pipeline and expand the reach of its RNAi technology over the years," said Ms. Vakiener. "I am excited to join the Board now to help contribute to its next phase of growth as Arrowhead takes the
PITTSBURGH, Dec. 02, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced the appointment of Curt Bradshaw, Ph.D., as its new Chief Scientific Officer. Dr. Bradshaw is a proven drug developer in the field of precision genetic medicines, coming to NeuBase from his most recent role as Chief Scientific Officer at Arrowhead Pharmaceuticals. In his new role, Dr. Bradshaw will be responsible for leading and expanding NeuBase’s PATrOL-enabled anti-gene pipeline and will serve as a key member of its executive management team. “
424B7 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
10-K - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
8-K - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)